Structure-based discovery of nonhallucinogenic psychedelic analogs
The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Drugs that target the human serotonin 2A receptor (5-HT 2A R) are used to treat neuropsychiatric diseases; however, many have hallucinogenic effects, hampering their use. Here, we present structures of 5-HT 2A R complexed with the psychedelic drugs psilocin (the active metabolite of psilocybin) and d -lysergic acid diethylamide (LSD), as well as the endogenous neurotransmitter serotonin and the nonhallucinogenic psychedelic analog lisuride. Serotonin and psilocin display a second binding mode in addition to the canonical mode, which enabled the design of the psychedelic IHCH-7113 (a substructure of antipsychotic lumateperone) and several 5-HT 2A R β-arrestin–biased agonists that displayed antidepressant-like activity in mice but without hallucinogenic effects. The 5-HT 2A R complex structures presented herein and the resulting insights provide a solid foundation for the structure-based design of safe and effective nonhallucinogenic psychedelic analogs with therapeutic effects.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Additionally, to target 5-HT 2A R, the combination of LSD and psilocybin can lead to biased activation of the mediated signaling pathway and produce antidepressant effects without the side effects of hallucinations. 387”
From Major depressive disorder: hypothesis, mechanism, prevention and treatment (2024) · cites this paper as [387]
In the citing paper
“While LSD binds to the orthosteric site of the 5-HT 2A R, certain ergoline-like analogs of LSD bind to the 5-HT 2A R at an extended binding pocket (Cao et al., 2022).”
From Psychedelics and Neural Plasticity: Therapeutic Implications (2022) · cites this paper as Cao et al., 2022
In the citing paper
“In a separate study, the psychedelic analog IHCH-7113 and several other 5-HT 2A R b -arrestin-biased agonists also demonstrate antidepressant-like activity in mice without hallucinogenic effects (Cao et al., 2022), although their dendritic and synaptic effects remain to be elucidated.”
From Psychedelics and Neural Plasticity: Therapeutic Implications (2022) · cites this paper as Cao et al., 2022
Citations
Cites
PHENIX : a comprehensive Python-based system for macromolecular structure solution
Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909052925 · Cited by 23,716
Kabsch, W. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909047337 · Cited by 16,463
Integration, scaling, space-group assignment and post-refinement
Kabsch, W. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909047374 · Cited by 2,528
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201
The expanded biology of serotonin
Berger, M., Gray, J. A., & Roth, B. L. (2009) · Annual Review of Medicine · doi:10.1146/annurev.med.60.042307.110802 · Cited by 2,100
Nichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762
Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698
Trial of Psilocybin versus Escitalopram for Depression
Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032994 · Cited by 1,391
Psilocybin with psychological support for treatment-resistant depression: six-month follow-up
Carhart-Harris, R. L., Bolstridge, M., Day, C. M. J., Rucker, J., Watts, R., Erritzoe, D. E., Kaelen, M., Giribaldi, B., Bloomfield, M., Pilling, S., et al. (2018) · Psychopharmacology · doi:10.1007/s00213-017-4771-x · Cited by 970
Operational models of pharmacological agonism
Black, J. W., & Leff, P. (1983) · Proceedings of the Royal Society of London. Series B. Biological Sciences · doi:10.1098/rspb.1983.0093 · Cited by 951
Research works printed but not linked: 3
- A. S. A. T. Shulgin PIHKAL: A Chemical Love Story (Transform Press 1991).
- A. S. A. T. Shulgin TIHKAL: The Continuation (Transform Press 1997).
- 10.1073/pnas.0708862105 · DOI · Paper page
Cited by
Major depressive disorder: hypothesis, mechanism, prevention and treatment
Cui, L., Li, S., Wang, S., Wu, X., Liu, Y., Yu, W., Wang, Y., Tang, Y., Xia, M., & Li, B. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01738-y · Cited by 1,244
“387 Thus, the administration of psilocybin can rapidly and persistently induce neuronal dendritic remodeling in the medial frontal cortex of mice, and the psilocybin-induced newly formed dendritic spines can successfully transform functional synapses, suggesting that synaptic rewiring may also be…”
BackgroundSelf-citationPsychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors
Vargas, M. V., Dunlap, L. E., Dong, C., Carter, S. J., Tombari, R. J., Jami, S. A., Cameron, L. P., Patel, S. D., Hennessey, J. J., Saeger, H. N., et al. (2023) · Science · doi:10.1126/science.adf0435 · Cited by 489
Psychedelics promote plasticity by directly binding to BDNF receptor TrkB
Moliner, R., Girych, M., Brunello, C. A., Kovaleva, V., Biojone, C., Enkavi, G., Antenucci, L., Kot, E. F., Goncharuk, S. A., Kaurinkoski, K., et al. (2023) · Nature Neuroscience · doi:10.1038/s41593-023-01316-5 · Cited by 478
The neural basis of psychedelic action
Kwan, A. C., Olson, D. E., Preller, K. H., & Roth, B. L. (2022) · Nature Neuroscience · doi:10.1038/s41593-022-01177-4 · Cited by 302
Default Mode Network Modulation by Psychedelics: A Systematic Review
Gattuso, J. J., Perkins, D., Ruffell, S., Lawrence, A. J., Hoyer, D., Jacobson, L. H., Timmermann, C., Castle, D., Rossell, S. L., Downey, L. A., et al. (2023) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyac074 · Cited by 256
“The same rationale also applies to non-hallucinogenic psychedelic analogues which are currently being explored and have shown anti-depressant effects, at least in rodent models (Cao et al., 2022).”
BackgroundBespoke library docking for 5-HT2A receptor agonists with antidepressant activity
Kaplan, A. L., Confair, D. N., Kim, K., Barros-Álvarez, X., Rodriguiz, R. M., Yang, Y., Kweon, O. S., Che, T., McCorvy, J. D., Kamber, D. N., et al. (2022) · Nature · doi:10.1038/s41586-022-05258-z · Cited by 245
AlphaFold2 structures guide prospective ligand discovery
Lyu, J., Kapolka, N., Gumpper, R., Alon, A., Wang, L., Jain, M. K., Barros-Álvarez, X., Sakamoto, K., Kim, Y., DiBerto, J., et al. (2024) · Science · doi:10.1126/science.adn6354 · Cited by 158
5-HT2ARs Mediate Therapeutic Behavioral Effects of Psychedelic Tryptamines
Cameron, L. P., Patel, S. D., Vargas, M. V., Barragan, E. V., Saeger, H. N., Warren, H. T., Chow, W. L., Gray, J. A., & Olson, D. E. (2023) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.2c00718 · Cited by 118
Psilocybin’s lasting action requires pyramidal cell types and 5-HT2A receptors
Shao, L.-X., Liao, C., Davoudian, P. A., Savalia, N. K., Jiang, Q., Wojtasiewicz, C., Tan, D., Nothnagel, J. D., Liu, R., Woodburn, S. C., et al. (2025) · Nature · doi:10.1038/s41586-025-08813-6 · Cited by 138
Wojtas, A., Bysiek, A., Wawrzczak‐Bargieła, A., Szych, Z., Majcher‐Maślanka, I., Herian, M., Maćkowiak, M., & Gołembiowska, K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126713 · Cited by 119
Becker, A., Klaiber, A., Holze, F., Istampoulouoglou, I., Duthaler, U., Varghese, N., Eckert, A., & Liechti, M. E. (2022) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyac075 · Cited by 117
Glatfelter, G. C., Pottie, E., Partilla, J. S., Sherwood, A. M., Kaylo, K., Pham, D. N. K., Naeem, M., Sammeta, V. R., DeBoer, S., Golen, J. A., et al. (2022) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.2c00177 · Cited by 89
Snapshot of the cannabinoid receptor 1-arrestin complex unravels the biased signaling mechanism
Liao, Y., Zhang, H., Shen, Q., Cai, C., Ding, Y., Shen, D., Guo, J., Qin, J., Dong, Y., Zhang, Y., et al. (2023) · Cell · doi:10.1016/j.cell.2023.11.017 · Cited by 95
“Selective” serotonin 5-HT2A receptor antagonists
Casey, A. B., Cui, M., Booth, R. G., & Canal, C. E. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115028 · Cited by 96
1Progress, applications, challenges and prospects of protein purification technology
Du, M., Hou, Z., Liu, L., Xuan, Y., Chen, X., Fan, L., Li, Z., & Xu, B. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.1028691 · Cited by 98
Self-citation5-HT2A receptors: Pharmacology and functional selectivity
Cummins, B. R., Billac, G. B., Nichols, D. E., & Nichols, C. D. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100059 · Cited by 86
Sekssaoui, M., Bockaert, J., Marin, P., & Bécamel, C. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-024-01794-6 · Cited by 89
Psychedelics and Neural Plasticity: Therapeutic Implications
Grieco, S. F., Castrén, E., Knudsen, G. M., Kwan, A. C., Olson, D. E., Zuo, Y., Holmes, T. C., & Xu, X. (2022) · The Journal of Neuroscience · doi:10.1523/jneurosci.1121-22.2022 · Cited by 82
“In a separate study, the psychedelic analog IHCH-7113 and several other 5-HT 2A R b -arrestin – biased agonists also demonstrate antide-pressant-like activity in mice without hallucinogenic effects (Cao et al., 2022), although their dendritic and synaptic effects remain to be elucidated.”
Duan, W., Cao, D., Wang, S., & Cheng, J. (2023) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00375 · Cited by 85
Self-citationThe polypharmacology of psychedelics reveals multiple targets for potential therapeutics
Jain, M. K., Gumpper, R. H., Slocum, S. T., Schmitz, G. P., Madsen, J. S., Tummino, T. A., Suomivuori, C., Huang, X.-P., Shub, L., DiBerto, J. F., et al. (2025) · Neuron · doi:10.1016/j.neuron.2025.06.012 · Cited by 88
Propofol exerts anti-anhedonia effects via inhibiting the dopamine transporter
Zhu, X., Li, J., Qiu, G., Wang, L., Lu, C., Guo, Y., Yang, K., Cai, F., Xu, T., Yuan, T., et al. (2023) · Neuron · doi:10.1016/j.neuron.2023.02.017 · Cited by 76
Self-citationJohnston, J. N., Kadriu, B., Allen, J., Gilbert, J. R., Henter, I. D., & Zarate, C. A. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109422 · Cited by 75
Therapeutic mechanisms of psychedelics and entactogens
Heifets, B. D., & Olson, D. E. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01666-5 · Cited by 79
Deep contrastive learning enables genome-wide virtual screening
Jia, Y., Gao, B., Tan, J., Zheng, J., Hong, X., Zhu, W., Tan, H., Xiao, Y., Tan, L., Cai, H., et al. (2026) · Science · doi:10.1126/science.ads9530 · Cited by 66
Zhao, X., Du, Y., Yao, Y., Dai, W., Yin, Y., Wang, G., Li, Y., & Zhang, L. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241249436 · Cited by 71
Differences across sexes on head-twitch behavior and 5-HT2A receptor signaling in C57BL/6J mice
Jaster, A. M., Younkin, J., Cuddy, T., Revenga, M. D. L. F., Poklis, J. L., Dozmorov, M. G., & González‐Maeso, J. (2022) · Neuroscience Letters · doi:10.1016/j.neulet.2022.136836 · Cited by 66
Functional screening and rational design of compounds targeting GPR132 to treat diabetes
Wang, J., Dou, X., Cheng, J., Gao, M., Xu, G., Ding, W., Ding, J.-H., Li, Y., Wang, S., Ji, Z.-W., et al. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00899-4 · Cited by 62
Self-citation5-MeO-DMT modifies innate behaviors and promotes structural neural plasticity in mice
Jefferson, S. J., Gregg, I., Dibbs, M., Liao, C., Wu, H., Davoudian, P. A., Woodburn, S. C., Wehrle, P. H., Sprouse, J. S., Sherwood, A. M., et al. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01572-w · Cited by 65
Psychedelics as Transformative Therapeutics
Roth, B. L., & Gumpper, R. H. (2023) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230172 · Cited by 58
Mechanisms and molecular targets surrounding the potential therapeutic effects of psychedelics
Jaster, A. M., & González‐Maeso, J. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02274-x · Cited by 61
Hashimoto, K. (2024) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-024-01770-7 · Cited by 61
Tolerance and Cross-Tolerance among Psychedelic and Nonpsychedelic 5-HT2A Receptor Agonists in Mice
Revenga, M. D. L. F., Jaster, A. M., McGinn, J., Silva, G. M., Saha, S., & González‐Maeso, J. (2022) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.2c00170 · Cited by 56
Structure-based design of non-hypertrophic apelin receptor modulator
Wang, W., Ji, S., Zhang, W., Zhang, J., Cai, C., Hu, R., Zang, S., Miao, L., Xu, H., Chen, L.-N., et al. (2024) · Cell · doi:10.1016/j.cell.2024.02.004 · Cited by 58
The Bright Side of Psychedelics: Latest Advances and Challenges in Neuropharmacology
Mastinu, A., Anyanwu, M., Carone, M., Abate, G., Bonini, S. A., Peron, G., Tirelli, E., Pucci, M., Ribaudo, G., Oselladore, E., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021329 · Cited by 57
Flexible scaffold-based cheminformatics approach for polypharmacological drug design
Chen, Z., Yu, J., Wang, H., Xu, P., Fan, L., Sun, F., Huang, S., Zhang, P., Huang, H., Gu, S., et al. (2024) · Cell · doi:10.1016/j.cell.2024.02.034 · Cited by 54
Self-citationWolf, G., Singh, S., Blakolmer, K., Lerer, L. B., Lifschytz, T., Heresco‐Levy, U., Lotan, A., & Lerer, B. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01832-z · Cited by 52
Structural studies of serotonin receptor family
Parajulee, A., & Kim, K. (2023) · BMB Reports · doi:10.5483/bmbrep.2023-0147 · Cited by 58
Isolation of psychedelic-responsive neurons underlying anxiolytic behavioral states
Muir, J., Lin, S., Aarrestad, I. K., Daniels, H. R., Ma, J., Tian, L., Olson, D. E., & Kim, C. K. (2024) · Science · doi:10.1126/science.adl0666 · Cited by 55
Elucidating pathway-selective biased CCKBR agonism for Alzheimer’s disease treatment
Wang, J., Sha, X.-Y., Shao, Y., Zhang, Z.-H., Huang, S.-M., Lin, H., Gan, S., Zhang, N., Xia, X., Sun, Y.-N., et al. (2025) · Cell · doi:10.1016/j.cell.2025.10.034 · Cited by 56
Self-citationThe structural diversity of psychedelic drug actions revealed
Gumpper, R. H., Jain, M. K., Kim, K., Sun, R., Sun, N., Xu, Z., DiBerto, J. F., Krumm, B. E., Kapolka, N. J., Kanıskan, H. Ü., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-57956-7 · Cited by 46
Molecular design of a therapeutic LSD analogue with reduced hallucinogenic potential
Tuck, J. R., Dunlap, L. E., Khatib, Y. A., Hatzipantelis, C. J., Novak, S. W., Rahn, R. M., Davis, A. R., Mosswood, A., Vernier, A. M. M., Fenton, E. M., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2416106122 · Cited by 50
Qu, Y., Chang, L., Ma, L., Wan, X., & Hashimoto, K. (2022) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2022.173500 · Cited by 48
Braun, D., Rosenberg, A. M., Rabaniam, E., Haruvi, R., Malamud, D., Barbara, R., Aiznkot, T., Levavi‐Sivan, B., & Kawashima, T. (2024) · Molecular Psychiatry · doi:10.1038/s41380-023-02391-7 · Cited by 41
Pharmacological inhibition of Kir4.1 evokes rapid-onset antidepressant responses
Zhou, X., Zhao, C., Xu, H., Xu, Y., Li, Z., Wang, P., He, J., Lu, T., Gu, Y., Yang, Y., et al. (2024) · Nature Chemical Biology · doi:10.1038/s41589-024-01555-y · Cited by 45
Self-citationNeuroimaging in psychedelic drug development: past, present, and future
Wall, M. B., Harding, R., Zafar, R. R., Rabiner, E. A., Nutt, D. J., & Erritzøe, D. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02271-0 · Cited by 46
Shahar, O., Botvinnik, A., Shwartz, A., Lerer, E., Golding, P., Buko, A., Hamid, E., Kahn, D., Guralnick, M., Blakolmer, K., et al. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02477-w · Cited by 40
“This therapeutic mechanism has received considerable emphasis in the development of novel, non-hallucinogenic, psychedelic agents [25 – 27].”
Psychedelics for acquired brain injury: a review of molecular mechanisms and therapeutic potential
Allen, J., Dames, S., Foldi, C. J., & Shultz, S. R. (2024) · Molecular Psychiatry · doi:10.1038/s41380-023-02360-0 · Cited by 47
The Effects of Psychedelics on Neuronal Physiology
Hatzipantelis, C. J., & Olson, D. E. (2023) · Annual Review of Physiology · doi:10.1146/annurev-physiol-042022-020923 · Cited by 44
PET brain imaging in neurological disorders
Xie, L., Zhao, J., Li, Y., & Bai, J. (2024) · Physics of Life Reviews · doi:10.1016/j.plrev.2024.03.007 · Cited by 43
Biased signaling in GPCRs: Structural insights and implications for drug development
Ma, Y., Patterson, B., & Zhu, L. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108786 · Cited by 40
Takaba, R., Ibi, D., Yoshida, K., Hosomi, E., Kawase, R., Kitagawa, H., Goto, H., Achiwa, M., Mizutani, K., Maeda, K., et al. (2023) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-023-02778-x · Cited by 39
Wulff, A. B., Nichols, C. D., & Thompson, S. M. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109504 · Cited by 41
Discovery of β-Arrestin-Biased 25CN-NBOH-Derived 5-HT2AReceptor Agonists
Poulie, C. B. M., Pottie, E., Simon, Í. A., Harpsøe, K., D’Andrea, L., Komarov, I. V., Gloriam, D. E. I., Jensen, A. A., Stove, C. P., & Kristensen, J. L. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00702 · Cited by 34
A Comprehensive Review of the Current Status of the Cellular Neurobiology of Psychedelics
Banushi, B., & Polito, V. (2023) · Biology · doi:10.3390/biology12111380 · Cited by 37
Floris, G., Dabrowski, K. R., Zanda, M. T., & Daws, S. E. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02788-y · Cited by 40
Aarrestad, I. K., Cameron, L. P., Fenton, E. M., Casey, A. B., Rijsketic, D. R., Patel, S. D., Sambyal, R., Johnson, S. B., Ly, C., Viswanathan, J., et al. (2025) · Nature Neuroscience · doi:10.1038/s41593-025-02021-1 · Cited by 43
Comparative Pharmacological Effects of Lisuride and Lysergic Acid Diethylamide Revisited
Glatfelter, G. C., Pottie, E., Partilla, J. S., Stove, C. P., & Baumann, M. H. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.3c00192 · Cited by 36
Pogorelov, V. M., Rodriguiz, R. M., Roth, B. L., & Wetsel, W. C. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1233743 · Cited by 36
Animal Behavior in Psychedelic Research
Odland, A. U., Kristensen, J. L., & Andreasen, J. T. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.122.000590 · Cited by 32
Cryo-EM structure of the human adenosine A 2B receptor–G s signaling complex
Chen, Y., Zhang, J., Weng, Y., Xu, Y., Lü, W., Liu, W., Liu, M., Hua, T., & Song, G. (2022) · Science Advances · doi:10.1126/sciadv.add3709 · Cited by 34
The crosstalk between 5-HT2AR and mGluR2 in schizophrenia
Saha, S., & González‐Maeso, J. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109489 · Cited by 33
Flower, J. E., Gibbons, W. J., Adams, A. M., Wang, X., Broude, C. N., & Jones, J. A. (2023) · Biotechnology and Bioengineering · doi:10.1002/bit.28480 · Cited by 30
Conformational dynamics underlying atypical chemokine receptor 3 activation
Otun, O., Aljamous, C., Nero, E. D., Arimont, M., Bosma, R., Zarzycka, B. A., Girbau, T., Leyrat, C., de Graaf, C., Leurs, R., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2404000121 · Cited by 29
Padawer-Curry, J. A., Krentzman, O. J., Kuo, C., Wang, X., Bice, A. R., Nicol, G. E., Snyder, A. Z., Siegel, J. S., McCall, J. G., & Bauer, A. Q. (2025) · Nature Neuroscience · doi:10.1038/s41593-025-02069-z · Cited by 36
Tabernanthalog Reduces Motivation for Heroin and Alcohol in a Polydrug Use Model
Heinsbroek, J. A., Giannotti, G., Bonilla, J., Olson, D. E., & Peters, J. (2023) · Psychedelic Medicine · doi:10.1089/psymed.2023.0009 · Cited by 32
Cao, D., Zhang, P., & Wang, S. (2024) · Neuron · doi:10.1016/j.neuron.2024.01.004 · Cited by 33
Self-citationPottie, E., Poulie, C. B. M., Simon, Í. A., Harpsøe, K., D’Andrea, L., Komarov, I. V., Gloriam, D. E. I., Jensen, A. A., Kristensen, J. L., & Stove, C. P. (2023) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.3c00267 · Cited by 33
Ketamine Analgesia and Psychedelia: Can We Dissociate Dissociation?
Mashour, G. A. (2022) · Anesthesiology · doi:10.1097/aln.0000000000004172 · Cited by 28
Wang, C., Li, Y., Yi, Y., Liu, G., Guo, R., Wang, L., Lan, T., Wang, W., Chen, X., Chen, S., et al. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02645-1 · Cited by 34
Psilocybin for the treatment of Alzheimer’s disease
Zheng, S., Ma, R., Yang, Y., & Li, G. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1420601 · Cited by 28
Humphreys, K. N., Korthuis, P. T., Stjepanović, D., & Hall, W. (2024) · Annual Review of Psychology · doi:10.1146/annurev-psych-020124-023532 · Cited by 32
Tasker, N. R., & Wipf, P. (2022) · Organic Letters · doi:10.1021/acs.orglett.2c02569 · Cited by 28
Ligand selectivity hotspots in serotonin GPCRs
Simon, Í. A., Bjørn-Yoshimoto, W. E., Harpsøe, K., Iliadis, S., Svensson, B. R., Jensen, A. A., & Gloriam, D. E. I. (2023) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2023.09.012 · Cited by 27
Glennon, R. A., & Dukat, M. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00157 · Cited by 29
Pharmacological and behavioural effects of tryptamines present in psilocybin‐containing mushrooms
Rakoczy, R. J., Runge, G. N., Sen, A. K., Sandoval, O., Wells, H. G., Nguyen, Q., Roberts, B., Sciortino, J. H., Gibbons, W. J., Friedberg, L. M., et al. (2024) · British Journal of Pharmacology · doi:10.1111/bph.16466 · Cited by 28
Introducing urea into tirapazamine derivatives to enhance anticancer therapy
Xu, Y., Lv, J., Kong, C., Liu, Y., Wang, K., Tang, Z., & Chen, X. (2024) · National Science Review · doi:10.1093/nsr/nwae038 · Cited by 25
Puigseslloses, P., Nadal‐Gratacós, N., Ketsela, G., Weiss, N., Berzosa, X., Estrada‐Tejedor, R., Islam, M. N., Holy, M., Niello, M., Pubill, D., et al. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02506-8 · Cited by 26
Emerging paradigms for target discovery of traditional medicines: A genome-wide pan-GPCR perspective
Bi, Z., Li, H., Liang, Y., Sun, D., Liu, S., Chen, W., Leng, L., Song, C., Zhang, S., Cong, Z., et al. (2025) · The Innovation · doi:10.1016/j.xinn.2024.100774 · Cited by 38
The science of psychedelic medicine
Siegel, J. S., Liston, C. M., Nicol, G. E., Carhart-Harris, R. L., & Bogenschutz, M. P. (2026) · Nature Medicine · doi:10.1038/s41591-025-04194-5 · Cited by 28
Robinson, G. I., Li, D., Wang, B., Zahoruiko, Y., Gerasymchuk, M., Hudson, D., Kovalchuk, O., & Kovalchuk, I. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45080427 · Cited by 24
Gattuso, J. J., Wilson, C., Hannan, A. J., & Renoir, T. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.16017 · Cited by 28
Aboharb, F., Davoudian, P. A., Shao, L.-X., Liao, C., Rzepka, G. N., Wojtasiewicz, C., Indajang, J., Dibbs, M., Rondeau, J. A., Sherwood, A. M., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-56850-6 · Cited by 27
A lexicon for psychedelic research and treatment
Nutt, D. J., Erritzøe, D., Schlag, A. K., Luke, D. P., Mash, D. C., Uchida, H., Aday, J. S., Rucker, J., Galindo, L., Sweeney, M., et al. (2025) · Drug Science Policy and Law · doi:10.1177/20503245251380511 · Cited by 25
Hack, L. M., Zhang, X., Heifets, B. D., Suppes, T. M., van Roessel, P., Yesavage, J. A., Gray, N. J., Hilton, R. A., Bertrand, C., Rodríguez, C. I., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42141-5 · Cited by 24
Psychedelics elicit their effects by 5-HT2A receptor-mediated Gi signalling
Xu, Z., Wang, H., Yu, J., Deng, Y., Tian, X., Ni, R., Xia, F., Yang, L., Xu, C., Zhang, L., et al. (2026) · Nature · doi:10.1038/s41586-025-10061-7 · Cited by 27
Self-citationPsychedelics action and schizophrenia
Maćkowiak, M. (2023) · Pharmacological Reports · doi:10.1007/s43440-023-00546-5 · Cited by 31
Psilocybin and Eugenol Reduce Inflammation in Human 3D EpiIntestinal Tissue
Robinson, G. I., Li, D., Wang, B., Rahman, T., Gerasymchuk, M., Hudson, D., Kovalchuk, O., & Kovalchuk, I. (2023) · Life · doi:10.3390/life13122345 · Cited by 28
The immunomodulatory effects of classical psychedelics: A systematic review of preclinical studies
Low, Z. X. B., Ng, W. S., Lim, E. S. Y., Goh, B. H., & Kumari, Y. (2024) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2024.111139 · Cited by 27
Disrupted Human–Dog Interbrain Neural Coupling in Autism‐Associated Shank3 Mutant Dogs
Ren, W., Yu, S. P., Guo, K., Lu, C., & Zhang, Y. (2024) · Advanced Science · doi:10.1002/advs.202402493 · Cited by 29
Ippolito, A., Vasudevan, S. R., Hurley, S., Gilmour, G., Westhorpe, F. G., Churchill, G. C., & Sharp, T. (2025) · British Journal of Pharmacology · doi:10.1111/bph.70109 · Cited by 25
Emerging mechanisms of psilocybin-induced neuroplasticity
Sonda, S., Pendin, D., Comai, S., Martin, S. D., Manfredi, P., & Mattarei, A. (2025) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2025.08.012 · Cited by 24
Wolfgang, A. S., & Hoge, C. W. (2023) · Current Psychiatry Reports · doi:10.1007/s11920-023-01446-4 · Cited by 25
Hu, J., Lian, Z., Weng, Z., Xu, Z., Gao, J. Y., Liu, Y., Luo, T., & Wang, X. (2024) · Advanced Materials · doi:10.1002/adma.202405547 · Cited by 22
Progress on the development of Class A GPCR‐biased ligands
Morales, P., Scharf, M. M., Bermúdez, M., Egyed, A., Franco, R., Hansen, O. K., Jagerovic, N., Jakubík, J., Keserű, G. M., Kiss, D. J., et al. (2024) · British Journal of Pharmacology · doi:10.1111/bph.17301 · Cited by 23
Mantas, I., Flais, I., Masarapu, Y., Ionescu, T. M., Frapard, S., Jung, F., Merre, P. L., Saarinen, M., Tiklová, K., Salmani, B. Y., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52429-9 · Cited by 21
Psychedelics: preclinical insights provide directions for future research
Gumpper, R. H., & Roth, B. L. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01567-7 · Cited by 21
Schmitz, G. P., Chiu, Y.-T., Foglesong, M. L., Magee, S. N., MacKinnon, M., König, G. M., Kostenis, E., Hsu, L.-M., Shih, Y.-Y. I., Roth, B. L., et al. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03611-0 · Cited by 31
Min, H., Sun, T., Cui, W., Han, Z., Yao, P., Cheng, P., & Shi, W. (2023) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.3c01025 · Cited by 20
Psilocybin: From Psychiatric Pariah to Perceived Panacea
Fonzo, G. A., Wolfgang, A. S., Barksdale, B. R., Krystal, J. H., Carpenter, L. L., Kraguljac, N. V., Grzenda, A. L., McDonald, W. M., Widge, A. S., Rodríguez, C. I., et al. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230682 · Cited by 20
Metadata
- Authors
- Cao, D., Yu, J., Wang, H., Luo, Z., Liu, X., He, L., Qi, J., Fan, L., Tang, L., Chen, Z., Li, J., Cheng, J., & Wang, S.
- Affiliations
- Chinese Academy of Sciences (CN)
- ShanghaiTech University (CN)
- Soochow University (CN)
- Corresponding author
- Cao, Dongmei
- Yu, Jing
- Wang, Huan
- Luo, Zhipu
- Liu, Xinyu
- Cheng, Jianjun
- Wang, Sheng
- ORCID
- Venue
- Science
- Published
- 2022-01-28
- Volume
- 375
- Issue
- 6579
- Pages
- 403-411
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W4210474529
- Cited by
- 312
- References
- 46
- Citations by year
- 2026: 50 · 2025: 77 · 2024: 84 · 2023: 69 · 2022: 32
- FWCI
- 59.96
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- 5-HT2A receptor, psilocin, LSD, lisuride, structure-based drug design, receptor-ligand complex, lumateperone, antidepressant-like effects, hallucinogenic effects
- MeSH terms
- Animals, Antidepressive Agents, Binding Sites, Hallucinations, Hallucinogens, Heterocyclic Compounds, 4 or More Rings, Humans, Ligands, Lisuride, Lysergic Acid Diethylamide, Protein Conformation, Psilocybin, Serotonin, Structure-Activity Relationship, Drug Design, Signal Transduction, Crystallography, X-Ray, Arrestin, Receptor, Serotonin, 5-HT2A, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.